See more : MEB Corporation Public Company Limited (MEB.BK) Income Statement Analysis – Financial Results
Complete financial analysis of Astria Therapeutics, Inc. (ATXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Astria Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- UltraTech Cement Limited (ULTRACEMCO.NS) Income Statement Analysis – Financial Results
- Gold Mountain Mining Corp. (GMTNF) Income Statement Analysis – Financial Results
- Sarama Resources Ltd (SWA.V) Income Statement Analysis – Financial Results
- Nidec Corporation (6594.T) Income Statement Analysis – Financial Results
- Shenzhen Longli Technology Co.,Ltd (300752.SZ) Income Statement Analysis – Financial Results
Astria Therapeutics, Inc. (ATXS)
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 26.00K | 119.00K | 0.00 | 395.00K | 202.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | -26.00K | -119.00K | 500.00K | -395.00K | -202.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 57.33M | 34.26M | 15.55M | 25.59M | 18.32M | 17.04M | 18.68M | 25.45M | 23.03M | 15.69M | 13.99M | 12.41K |
| General & Administrative | 25.70M | 19.24M | 14.81M | 11.85M | 8.77M | 9.33M | 8.91M | 10.11M | 8.63M | 6.00M | 4.13M | 3.27K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 718.00 |
| SG&A | 25.70M | 19.24M | 14.81M | 11.85M | 8.77M | 9.33M | 8.91M | 10.11M | 8.63M | 6.00M | 4.13M | 3.98K |
| Other Expenses | 0.00 | -55.00K | -58.00K | -101.00K | -50.00K | 176.00K | 32.00K | 93.00K | 7.00K | 3.00K | 1.00K | 0.00 |
| Operating Expenses | 83.03M | 53.50M | 30.36M | 37.44M | 27.09M | 26.37M | 27.59M | 35.56M | 31.66M | 21.68M | 18.12M | 15.67K |
| Cost & Expenses | 83.03M | 53.50M | 30.36M | 37.44M | 27.09M | 26.37M | 27.59M | 35.56M | 31.66M | 21.68M | 18.12M | 15.67K |
| Interest Income | 10.20M | 1.72M | 122.00K | 236.00K | 845.00K | 425.00K | 160.00K | 242.00K | 0.00 | 0.00 | 0.00 | 4.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 462.00K | 837.00K | 978.00K | 206.00K | 0.00 | 0.00 |
| Depreciation & Amortization | -15.20M | 228.49K | -164.62M | 26.00K | 26.00K | 119.00K | 304.00K | 395.00K | 202.00K | 248.00K | 320.00K | 327.00 |
| EBITDA | -83.03M | -53.50M | -194.98M | -37.44M | -26.27M | -25.65M | -26.60M | -34.83M | -31.46M | -21.43M | -17.80M | -15.34M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,319.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -83.03M | -53.50M | -194.98M | -37.44M | -27.09M | -26.37M | -27.09M | -35.56M | -31.66M | -21.68M | -18.12M | -15.67K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,418.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.14M | 1.67M | 64.00K | 135.00K | 795.00K | 501.00K | -270.00K | -502.00K | -971.00K | -203.00K | 1.00K | 4.00 |
| Income Before Tax | -72.89M | -51.83M | -194.91M | -37.30M | -26.29M | -25.87M | -27.36M | -36.06M | -32.63M | -21.88M | -18.12M | -15.67K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,472.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.67M | -164.74M | -236.00K | -50.00K | 601.00K | 494.00K | 930.00K | 783.00K | 209.00K | 0.00 | 0.00 |
| Net Income | -72.89M | -50.17M | -30.17M | -37.06M | -26.24M | -25.87M | -27.36M | -36.06M | -32.63M | -21.88M | -18.12M | -15.67K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5,472.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.42 | -3.43 | -3.38 | -12.12 | -14.06 | -30.71 | -75.73 | -133.31 | -243.45 | -151.53 | -125.45 | -0.11 |
| EPS Diluted | -2.42 | -3.43 | -3.38 | -12.12 | -14.06 | -30.71 | -75.73 | -133.31 | -243.45 | -151.53 | -125.45 | -0.11 |
| Weighted Avg Shares Out | 30.12M | 14.62M | 8.93M | 3.06M | 1.87M | 842.47K | 361.36K | 270.50K | 134.03K | 144.42K | 144.42K | 144.42K |
| Weighted Avg Shares Out (Dil) | 30.12M | 14.62M | 8.93M | 3.06M | 1.87M | 842.47K | 361.36K | 270.50K | 134.03K | 144.42K | 144.42K | 144.42K |
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 32,500 shares of Astria's common stock on December 2, 2024 under Astria's 2022 Inducement Stock Incentive Plan....
Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema
Astria Therapeutics, Inc.'s STAR-0215 shows 90-96% reduction in HAE attack frequency, with a twice-a-year dosing regimen, positioning it as a transformative therapy. The company has a strong cash balance of $344 million, ensuring a runway until 2027, supporting continued development...
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. “We had another strong quarter...
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 52,000 shares of Astria's common stock on October 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan....
Astria Therapeutics to Present at Upcoming Global Angioedema Forum
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts will present two posters at the Global Angioedema Forum (GAF) in Copenhagen, Denmark on October 4-5,...
Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial navenibart ALPHA-STAR data at the upcoming European Academy of Dermatology and Venereology (EADV) Congress in...
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 180,000 shares of Astria's common stock on September 3, 2024 under Astria's 2022 Inducement Stock Incentive Plan....
Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5th in New York, New...
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 40,000 shares of Astria's common stock on June 3, 2024 under Astria's 2022 Inducement Stock Incentive Plan....
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference...
Source: https://incomestatements.info
Category: Stock Reports